Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04969861
Title BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nektar Therapeutics

oral squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral cavity cancer

laryngeal squamous cell carcinoma

hypopharynx cancer


NKTR-214 + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA | ITA | FRA | AUT

No variant requirements are available.